InflaRx Shares Surge 69% on Positive INF904 Phase 2a Results

Introduction

INFLARX N V (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company headquartered in Jena and Munich, Germany, with a subsidiary in Ann Arbor, Michigan. The company utilizes proprietary anti-C5a and anti-C5aR technologies to develop inhibitors of the complement activation factor C5a and its receptor C5aR, focusing on various inflammatory and autoimmune diseases.

Corporate Structure

Founded in 2007, INFLARX employs approximately 51–200 staff across its locations in Germany and the United States. The organization’s leadership team possesses extensive experience in immunology research, clinical development, and regulatory affairs. InflaRx conducts in-house research for its antibody and small-molecule programs and collaborates with partners such as Beijing Defengrei Biotechnology and Merck & Co.

Biopharmaceuticals by little plant

Recent Developments and News

On November 10, 2025, InflaRx filed Form 6-K with the U.S. Securities and Exchange Commission, reporting topline results from its Phase 2a basket study of INF904, an oral C5aR inhibitor. In hidradenitis suppurativa (HS), the data indicated reductions in abscess and nodule counts, pain relief, and improvement in Dermatology Life Quality Index scores through four weeks post-treatment. In chronic spontaneous urticaria (CSU), the 60 mg cohort reported a decrease in Urticaria Activity Score (UAS7) beginning from Week 1. On the same day, the company announced its third quarter 2025 financial and operating results via Form 6-K and held an investor webcast.

The company resolved earlier compliance challenges when, on September 11, 2025, it confirmed that its ordinary shares had traded above the Nasdaq minimum bid price requirement of $1.00 for ten consecutive business days, thereby restoring compliance with Listing Rule 5450(a)(1).

In April 2023, the U.S. Food and Drug Administration issued an Emergency Use Authorization for GOHIBIC (vilobelimab) for the treatment of hospitalized adults with COVID-19-associated acute respiratory distress syndrome (ARDS) when initiated within 48 hours of invasive mechanical ventilation or ECMO. GOHIBIC remains authorized solely under the pandemic EUA, with associated risks of serious infections and hypersensitivity reactions.

InflaRx has released several research findings, including a post-hoc analysis published in the British Journal of Dermatology on October 13, 2025, and a review in the International Journal of Molecular Sciences discussing vilobelimab’s role in sepsis and ARDS. The company plans to present data at the EADV Congress in Paris (September 17–19, 2025) and participate in the Guggenheim Securities Healthcare Innovation Conference (November 10–12, 2025).

Financial and Strategic Analysis

As of November 10, 2025, INFLARX shares closed at $2.08, an increase of 69.11% on a volume of 16,979,438 shares. This increase coincided with the release of Phase 2a data for INF904. InflaRx's market capitalization is approximately $83 million, with no dividend payouts reported and a beta of 1.49.

The company's pipeline includes:

• Vilobelimab (GOHIBIC), an anti-C5a monoclonal antibody involved in late-stage trials for hidradenitis suppurativa and other conditions.
• INF904, an oral C5aR inhibitor currently advancing through Phase 2 for HS and CSU.
• Early-stage programs (IFX002, INF905) aimed at other chronic inflammatory conditions.

Key partnerships support the company's global development and potential commercialization efforts in Europe and the U.S. InflaRx focuses on complement inhibition, addressing needs in rare and severe inflammatory diseases. However, the reliance on preliminary data and the absence of head-to-head comparisons could pose regulatory and competitive risks. Cash requirements will depend on upcoming trial milestones and potential licensing agreements.

Market Position and Industry Context

The global market for immunomodulatory therapies is competitive, featuring biologics that target TNF-α, IL-17, and IL-23 pathways. InflaRx differentiates itself with a focus on selective complement inhibition, a mechanism supported by increasing scientific validation. Within Germany’s biotechnology sector—where manufacturing contributed 26.6% of gross value in 2021—InflaRx operates among peers concentrating on rare diseases and inflammatory conditions. The company's focus on C5a/C5aR positions it within segments underserved by existing therapies, although macroeconomic factors and evolving regulatory landscapes in both Europe and the U.S. may influence trial timelines and market access.

tl;dr

On November 10, 2025, InflaRx announced topline data for INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, resulting in a 69.11% increase in share price to $2.08 on significant trading volume. The company also reported Q3 2025 results via Form 6-K and conducted an investor webcast. Compliance was restored on September 11, 2025, after meeting Nasdaq bid-price requirements. InflaRx will present findings at upcoming scientific meetings and advance its complement-targeting pipeline through ongoing trials, with a focus on rare inflammatory indications.